Pharma Acuity: Helping Biopharma companies bring better therapies to patients faster PharmaAcuity helps Biopharma companies accelerate clinical trials and commercialization by: o Merging the right combination of situational assessment, data strategy, analysis, and stakeholder engagement with o Diverse, comprehensive and interlinked datasets, sophisticated software and the most effective AI models, and o Aligning these with our team of experienced data scientists, therapy area advisors and commercial partners Our insights span across: o The most appropriate HCP opinion leaders (Key opinion leaders, Emerging Leaders, Digital Leaders) segmented by their knowledge, voice or influence o Best fit, efficient and productive trial sites o High performing principal investigators o Diverse and relevant patient populations o Treating physicians and institutions o Early adopters o Deep analysis of your competitive landscape and much more Our insights are be used to identify, segment and engage the high leverage stakeholders in the healthcare ecosystem to provide you with higher quality solutions, faster and at a better price point so you can bring your products to market in the most effective fashion.
External link for PharmaAcuity
Old Greenwich, CT 06870, US
New Delhi, IN
Budapest, HU
Super excited to share our article about how PharmaAcuity is harnessing Gen-AI to supercharge competitive intelligence to help build next generation TPPs. Would love to connect to learn how you're approaching this today and how we can accelerate your path to approval.
Harnessing Gen-AI to supercharge competitive intelligence for your Target Product Profile
Sharing our article on how Pharma Acuity uses Gen-AI to rapidly build and update your Target Product Profile. Would love to hear your thoughts on challenges you may have experienced building and managing your TPP through your development and launch cycle.
Harnessing Gen-AI to supercharge competitive intelligence for your Target Product Profile
Loved this post by Google CMO Lorraine Twohill. We are fortunate that at Pharma Acuity we started working with AI in the early days. The messages from Lorraine that really resonated are: 1) We are in the early days of AI and we need to work together to shape its future. 2) It is incumbent upon us as leaders to lead by example by experimenting with AI. 3) We have to give EVERY member of our team the latitude to experiment, innovate, share their ideas and demonstrate the benefits as well as challenges.
𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗔𝗜 𝗶𝘀𝗻'𝘁 𝘀𝗲𝘁 - 𝘄𝗲 𝗰𝗮𝗻 𝘀𝗵𝗮𝗽𝗲 𝗶𝘁 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿. There is a lot of both excitement and fear in our industry when it comes to AI. And everyone is trying to work out how to get started and how to help their teams on this journey. There is also this perception AI will threaten the very nature of creativity. I wholeheartedly disagree. Just like every other technology or tool that creatives have been able to work with, they will do amazing things with AI that surprise and delight us all, we are already seeing this. I get asked a lot about what leaders should do in this moment, so ahead of #Cannes next week, I shared my perspective on how to get started in a piece with Fortune Magazine. If I’ve figured out anything in 20 years at Google, it’s that we shape technology by using it. So use it! AI tools are already available, there’s no need for advanced training or coding knowledge to take part. Here are a few things I’ve learned and how we can all embrace this moment: 💡It starts at the top. As leaders, it’s on all of us to help our teams by building a culture of curiosity and experimentation, and we need to get hands-on ourselves and use these tools at work and in life. I love using AI to summarize entire email threads or give me feedback on how our creative work will be received. 💡Give your teams permission to innovate. Great ideas come from anywhere. So encourage everyone in your team to try various AI tools and share their best ideas! 💡There is no wrong way to experiment. Identifying a specific pain point is one way people get started. 💡For many creatives, a blank page can be terrifying. So put the horror of the first terrible draft on AI. Spare yourself. Then be brilliant. Check out the piece here, and let me know how you and your teams are using AI today - we can all learn from each other! https://lnkd.in/gtZ_bBnk And if you want to get your creative juices flowing, check out our AI Essentials course to learn how to use GenAI tools in your life: https://lnkd.in/gNEthfJh #AI #Marketing #Creativity #CannesLions2024 Google
Hello everyone, here is a quick recap of the social media trends from #ASCO24 So excited to see all the great conversations around cutting-edge innovation in #oncology #congresscoverage #socialmedia
PharmaAcuity reposted this
Excited to share a post on #ASCO24 generated from our Congress Coverage platform.
ASCO 2024 Highlight - MERUS PharmaAcuity’s congress coverage platform, PA AI, will be sharing a daily highlight from @ASCO 2024 that created interest on social media. As one of the hottest weeks in cancer science is winding down, the online world is still abuzz with chatter about the conference. One of the key areas of chatter was about Merus (Nasdaq: MRUS), a clinical-stage oncology company. Merus presented Petosemtamab interim data which showed clinically meaningful activity in previously treated head and neck squamous cell carcinoma: - Merus announced Tuesday that the combination of its development stage therapeutic Petosemtamab and the checkpoint inhibitor Keytruda reduced tumor size in 62% of patients with head and neck cancer, based on an interim analysis of an ongoing mid-stage clinical study. Merus (MRUS) experienced a significant bump in it’s share of voice, with folks expressing enthusiasm about the data that was presented.
Excited to share a post on #ASCO24 generated from our Congress Coverage platform.
ASCO 2024 Highlight - MERUS PharmaAcuity’s congress coverage platform, PA AI, will be sharing a daily highlight from @ASCO 2024 that created interest on social media. As one of the hottest weeks in cancer science is winding down, the online world is still abuzz with chatter about the conference. One of the key areas of chatter was about Merus (Nasdaq: MRUS), a clinical-stage oncology company. Merus presented Petosemtamab interim data which showed clinically meaningful activity in previously treated head and neck squamous cell carcinoma: - Merus announced Tuesday that the combination of its development stage therapeutic Petosemtamab and the checkpoint inhibitor Keytruda reduced tumor size in 62% of patients with head and neck cancer, based on an interim analysis of an ongoing mid-stage clinical study. Merus (MRUS) experienced a significant bump in it’s share of voice, with folks expressing enthusiasm about the data that was presented.
ASCO 2024 Highlight - MERUS PharmaAcuity’s congress coverage platform, PA AI, will be sharing a daily highlight from @ASCO 2024 that created interest on social media. As one of the hottest weeks in cancer science is winding down, the online world is still abuzz with chatter about the conference. One of the key areas of chatter was about Merus (Nasdaq: MRUS), a clinical-stage oncology company. Merus presented Petosemtamab interim data which showed clinically meaningful activity in previously treated head and neck squamous cell carcinoma: - Merus announced Tuesday that the combination of its development stage therapeutic Petosemtamab and the checkpoint inhibitor Keytruda reduced tumor size in 62% of patients with head and neck cancer, based on an interim analysis of an ongoing mid-stage clinical study. Merus (MRUS) experienced a significant bump in it’s share of voice, with folks expressing enthusiasm about the data that was presented.